We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
- Authors
Hennessy, B T; Gauthier, A M; Michaud, L B; Hortobagyi, G; Valero, V
- Abstract
Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer. Post-marketing use of capecitabine at the FDA-approved dose (2500 mg/m2/day) leads to unacceptable toxicity in many patients. Dose reductions anecdotally improve tolerability without compromising efficacy. This retrospective analysis was designed to verify these anecdotal reports.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Vol 16, Issue 8, p1289
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdi253